Ultragenyx Pharmaceutical (RARE) News Today

Ultragenyx Pharmaceutical (NASDAQ:RARE) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports.

Clearbridge Investments LLC lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 0.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,400,854 shares of the biopharmaceutical company's st

Cantor Fitzgerald reiterated an "overweight" rating and issued a $115.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Monday.

Russell Investments Group Ltd. trimmed its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 18.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,141 shares of the biopharmaceutical comp

BNP Paribas Financial Markets decreased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 87.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,893 shares of the biopharmaceutical company's s

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 513.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 507,095 sha

Wedbush reiterated a "neutral" rating and set a $45.00 price target on shares of Ultragenyx Pharmaceutical in a report on Thursday.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) has received an average rating of "Moderate Buy" from the fourteen ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating t

Susquehanna Fundamental Investments LLC purchased a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,005 shares of the

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totalling 4,240,000 shares, a drop of 15.9% from the June 15th total of 5,040,000 shares. Based on an average trading volume of 876,500 shares, the days-to-cover ratio is presently 4.8 days.

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 113.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 230,767 sh

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) Director Corazon (Corsee) D. Sanders sold 584 shares of the company's stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $40.98, for a total transaction of $23,932.32. Following the completion of the transaction, the director now owns 12,009 shares of the company's stock, valued at $492,128.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 1.8%

Vanguard Group Inc. raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 19.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,673,432 shares of the bioph

Wellington Management Group LLP trimmed its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,415,029 shares of the biopharmaceuti

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 3.7%

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Wedbush issued their Q1 2026 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Friday, June 14th. Wedbush analyst L. Chico anticipates that the biopharmaceutical c

Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Unusually-High Trading Volume

Great Point Partners LLC cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 10.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 648,000 shares of the biopharmaceutical company

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down After Insider Selling

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) EVP Karah Herdman Parschauer sold 9,806 shares of the business's stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $441,270.00. Following the completion of the sale, the executive vice president now directly owns 57,981 shares of the company's stock, valued at approximately $2,609,145. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading 8.6% Higher

Cantor Fitzgerald restated an "overweight" rating and issued a $115.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday.

First Light Asset Management LLC cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 33.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 744,665 shares of the b

Avidity Partners Management LP grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 55.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 844,500 shares of the biophar

Avoro Capital Advisors LLC cut its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 76.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 350,000 shares of the biopharmaceutical

Seven Eight Capital LP increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 140.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,906 shares of the biopharmaceutical compa

RTW Investments LP raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,887,086 shares of the biopharmaceutical company's stock af

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up to $41.45